grant
T-cell plasticity mediating treatment resistance and side effects in atopic dermatitis
Organization ICAHN SCHOOL OF MEDICINE AT MOUNT SINAILocation NEW YORK, UNITED STATESPosted 1 Sept 2025Deadline 31 Aug 2030
NIHUS FederalResearch GrantFY2025ATACAffectAreaAtopic DermatitisAtopic EczemaAtopic NeurodermatitisB cell growth factorB-Cell Differentiation Factor-1B-Cell Growth Factor-1B-Cell Growth Factor-IB-Cell Proliferating FactorB-Cell Stimulating FactorB-Cell Stimulating Factor-1B-Cell Stimulation Factor-1B-Cell Stimulatory Factor-1BCDF-1BCGFBCGF-1BCSF 1BSF-1BSF1BehaviorBinetrakinBiopsyBlepharitisBlocking AntibodiesBody TissuesCCL20CCL20 geneCRG-2CXCL10CXCL10 geneCXCL9CXCL9 geneCell BodyCell IsolationCell SegregationCell SeparationCell Separation TechnologyCell-Mediated Lympholytic CellsCellsCharacteristicsChemokine, CC Motif, Ligand 20ChildhoodChronicChronic DiseaseChronic IllnessClinicalClinical Treatment MoabConjunctivitisCutaneousCutaneous DisorderCytolytic T-CellCytotoxic T CellCytotoxic T-LymphocytesDataDefense MechanismsDermalDermatitisDermatologic biopsyDermatosesDevelopmentDiseaseDisorderDisseminated NeurodermatitisEczemaEczematous DermatitisExanthemExanthemaExodus 1FDA approvedFlareFrequenciesFutureGene TranscriptionGenetic TranscriptionGoalsHead and NeckHead and neck structureHumanHumigIFI10IL-13IL-22IL-4IL13IL4 ProteinINP10IP-10ImmuneImmune RegulatorsImmune TargetingImmune systemImmunesImmunomodulatorsIn VitroIndividualInflammationInflammatoryInterleukin-13Interleukin-4Interleukin-4 PrecursorKnowledgeLARCLPTNLesionLife StyleLifestyleLymphocyte Stimulatory Factor 1Lymphoid CellMCGF-2MHC ReceptorMIG GeneMIP3AMOB-1Macrophage Inflammatory Protein 3-AlphaMajor Histocompatibility Complex ReceptorMast Cell Growth Factor-2MediatingModalityModelingModern ManModernizationMolecularMolecular FingerprintingMolecular ProfilingMonoclonal AntibodiesParasitic infectionPathologicPathway interactionsPatientsPatternPhase 3 Clinical TrialsPhase III Clinical TrialsProductionProteomicsPsoriasisQOLQuality of lifeRNA ExpressionRashReactionResearchResistanceResistance developmentResistant developmentSCM-1SCM-1aSCM1SCYA20SCYB10SCYB9SCYC1SeveritiesSkinSkin DiseasesSkin Diseases and ManifestationsSkin RashSmall Inducible Cytokine Subfamily A, Member 20Spatial DistributionT cell receptor repertoire sequencingT cell receptor sequencingT-Cell Antigen ReceptorsT-Cell Growth Factor 2T-Cell ReceptorT-CellsT-LymphocyteTCR repertoire sequencingTCR sequencingTCR-seqTCRseqTechniquesTestingTh-2 CellTh2 CellsTherapeuticTherapeutic antibodiesTimeTissuesTranscriptionType 2 Helper CellXCL1XCL1 geneallergic dermatitisallergic eczemacell sortingchronic disorderclinical remissioncrg-10cutaneous biopsycutaneous diseasecutaneous lesionscytokinecytotoxicdermal diseasedermal disorderdermal lesiondeveloping resistancedevelopmentaldisabilityeczematouseffective therapyeffective treatmentepigenomicsgIP-10immune microenvironmentimmune modulatorsimmunomodulatory moleculesimmunoregulatorimmunoregulatory moleculesimmunosuppressive microenvironmentimmunosuppressive tumor microenvironmentimprovedindexinginfected with parasitesinnovateinnovationinnovativeinterleukin-22killer T cellmAbsmolecular profilemolecular signaturemonoclonal Absmultiomicsmultiple omicsmultiplex assaynew markernovelnovel biomarkernovel markerpanomicsparasite infectionpathwaypatient subclasspatient subclusterpatient subgroupspatient subpopulationspatient subsetspatient subtypespediatricphase III protocolpsoriasiformpsoriaticpsychological defense mechanismresistance to therapyresistantresistant to therapyresponders and non-respondersresponders from non-respondersresponders or non-respondersresponders versus non-respondersresponders vs non-respondersresponders/nonrespondersresponseresponse to therapyresponse to treatmentscATAC sequencingscATAC-seqscRNA sequencingscRNA-seqside effectsingle cell ATAC-seqsingle cell ATAC-sequencingsingle cell Assay for Transposase Accessible Chromatin sequencingsingle cell RNA-seqsingle cell RNAseqsingle cell expression profilingsingle cell sequencing assay for transposase accessible chromatinsingle cell transcriptomic profilingsingle-cell Assay for Transposase-Accessible Chromatin with sequencingsingle-cell RNA sequencingsingle-cell assay for transposase-accessible chromatin using sequencingsingle-cell assay for transposase-accessible chromatin-seqskin biopsyskin disorderskin lesionspatial RNA sequencingspatial gene expression analysisspatial gene expression profilingspatial resolved transcriptome sequencingspatial transcriptome analysisspatial transcriptome profilingspatial transcriptome sequencingspatial transcriptomicsspatially resolved transcriptomicsspatio transcriptomicsspheroidstargeted drug therapytargeted drug treatmentstargeted therapeutictargeted therapeutic agentstargeted therapytargeted treatmenttherapeutic resistancetherapeutic responsetherapy resistanttherapy responsethymus derived lymphocytetransdifferentiationtreatment resistancetreatment responsetreatment responsivenesstreatment strategytumor immune microenvironmenttumor-immune system interactions
Description preview
PROJECT SUMMARY
Type 2 inflammation is mediated by a specific branch of the immune system, assumed to have developed as a
major defense mechanism against parasitic infections and infestations. However, in our modern lifestyle, this
kind of immune axis is mostly encountered in the context of pathological activation, especially in inflammatory…
🔒
Start 7-day free trial — $29.99/mo →Full details available on the Agency plan
Unlock the complete grant description, eligibility criteria, contract value, evaluation details and apply link — plus alerts, pipeline tracking, and CSV export.
Agency Plan
7-day free trialUnlock procurement & grants
Upgrade to access active tenders from World Bank, UNDP, ADB and more — with email alerts and pipeline tracking.
$29.99 / month
- 🔔Email alerts for new matching tenders
- 🗂️Track tenders in your pipeline
- 💰Filter by contract value
- 📥Export results to CSV
- 📌Save searches with one click